Strong Revenue and EBITDA Growth
Q3 2024 saw revenue increase by 11.9% to $1.35 billion and adjusted EBITDA increase by 13.4% to $269.3 million.
Increase in Discharges and Same-Store Growth
Total discharges increased by 8.8%, with same-store discharges up 6.8%. Neurological and stroke conditions grew by 9% and 9.7%, respectively.
Guidance Increase for 2024
Encompass Health increased 2024 guidance with expected revenue of $5.325 billion to $5.375 billion and adjusted EBITDA of $1.07 billion to $1.09 billion.
Expansion and Prefabrication Strategy
99 beds were added during Q3, including two de novo hospitals. The Houston project, a fully prefabricated hospital, marks a significant milestone in construction strategy.
Reduced Bad Debt Expense
Bad debt expense as a percent of revenue was reduced to 1.9%, down 30 basis points from Q3 '23.
Strong Free Cash Flow and Low Leverage
Adjusted free cash flow increased by 27.1% to $189.7 million with net leverage at 2.3x.